Archive for July, 2019

$GNPX Initiates First Phase of Branding Lead Drug Candidate

Clinical-stage gene therapy company Genprex (NASDAQ: GNPX) this morning announced it has initiated the first phase of branding its lead drug candidate, Oncoprex(TM) immunogene therapy, and has completed and submitted non-proprietary drug name selections to the American Medical Association’s United States Adopted Names (“USAN”) Council. According to the update, Genprex will, upon receipt of USAN feedback expected later this year, submit its non-proprietary drug name selections to the World Health Organization for International Nonproprietary Names (“INN”) status. By mid-2020, the company expects to obtain an approved non-proprietary drug name. “Developing and obtaining regulatory approval of a non-proprietary drug name is a requirement for bringing our lead drug candidate to market,” Genprex Chairman and CEO Rodney Varner said in the news release. “We’re one step closer to achieving this regulatory milestone. An approved non-proprietary drug name will also make our lead drug candidate more widely recognizable to clinicians and physicians and most importantly, to patients living with non-small cell lung cancer.”

To view the full press release, visit: http://nnw.fm/1eKb3

About Genprex Inc.

Genprex, Inc. is a clinical stage gene therapy company developing potentially life-changing technologies for cancer patients, based upon a unique proprietary technology platform, including Genprex’s initial product candidate, Oncoprex(TM) immunogene therapy for non-small cell lung cancer (NSCLC). Genprex’s platform technologies are designed to administer cancer fighting genes by encapsulating them into nanoscale hollow spheres called nanovesicles, which are then administered intravenously and taken up by tumor cells where they express proteins that are missing or found in low quantities. Oncoprex has a multimodal mechanism of action whereby it interrupts cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis, or programmed cell death, in cancer cells, and modulates the immune response against cancer cells. Oncoprex has also been shown to block mechanisms that create drug resistance. For more information, visit the company’s website at www.Genprex.com.

NOTE TO INVESTORS: The latest news and updates relating to GNPX are available in the company’s newsroom at http://nnw.fm/GNPX

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

Wednesday, July 31st, 2019 Uncategorized Comments Off on $GNPX Initiates First Phase of Branding Lead Drug Candidate

$CNPOF $RIV Cannabis Edibles Market Projected to Quadruple in U.S. and Canada to $4.1 Billion

Palm Beach, FL – July 31, 2019 – A recent article from Green Entrepreneur quoting an ArcView report discussed the impending growth of the CBD edibles markets and its eventual superiority over smoked marijuana in terms of users and revenues. Observers have for quite a while have been seeing this rise in edibles coming. In 2017 in both the U.S. and Canada edible revenues were only $1 billion but they have since moved at a rapid pace and have become mainstream, garnering a massive new audience. ArcView said: “Legal cannabis-derived edible products, from candy and chocolate to infused beverages, is a sector worth watching over the next few years,” the report stated. Other highlights from their report were that Edibles are projected to grow from 12 percent to 14 percent of the total cannabis market by 2022, while flower drops from 50 percent to 36 percent and that edibles’ share of the total cannabis market has already more than doubled, from 5.4 percent in 2011 to the current 12 percent.   Active companies in the industry making moves to ready that include:  IONIC Brands Corp. (OTC: IONKF) (CSE: IONC), Origin House (OTCQX: ORHOF) (CSE:OH), MedMen Enterprises Inc. (OTCQX: MMNFF) (CSE: MMEN), Trulieve Cannabis Corp. (OTCPK: TCNNF) (CSE: TRUL), Canopy Rivers Inc. (OTCPK: CNPOF) (TSX-V: RIV).

Another report from BDS Analytics added that the place where these increased edibles will be sold will be/has been in dispensaries. They projected that overall, CBD sales are expected to surge to $20 billion by 2024; up substantially from the $1.9 billion in 2018. They track current and ongoing retail sales as well as consumer behavior. Retail tracking and forecast models include products sold through licensed dispensaries, pharmaceuticals and in general market retail, encompassing the full CBD market.

IONIC Brands Corp., (CSE: IONC) (OTC: IONKF) BREAKING NEWS:  IONIC Brands is pleased to announce that PharmaCann LLC’s (“PharmaCann”) Illinois dispensaries are exclusively launching Zoots Cannabis Infused Edibles and will be available this month, providing consistent relief for medical cannabis patients.

Verilife dispensaries, owned and operated by national vertically integrated cannabis operator PharmaCann, will offer drops, chews and energy shots from the Zoots line of products.  “Zoots is an ideal fit for Illinois medical cannabis patients seeking relief through a premium edible product that delivers consistent and reliable results,” said Brett Novey, Chief Operating Officer for PharmaCann. “We are excited to offer Illinois patients access to the Zoots line of premium edible products initially through our Verilife branded dispensaries, with plans to extend this offering to patients throughout the entire state of Illinois via our extensive wholesale network.”

For PharmaCann, quality was a vital factor when choosing Zoots for its Illinois dispensaries. What sets Zoots apart is its proprietary Cypress Extraction System®, which delivers a cannabis extract that is pure, consistent, and developed specifically for use as a premium-quality food ingredient. The developers of Zoots also have extensive experience in food processing and, as a result, all Zoots products are manufactured according to the FDA’s guidelines for food safety.  “Zoots has a strong reputation for its dedication to excellence, as does PharmaCann, making for a great partnership,” said Michael Devlin, co-founder of Zoots. “Our brand and products are built on a promise of providing high-quality and safe products.”

Created in hand-crafted small batches, the edibles are made with Cypress Extract™ of cannabis paired with unique flavor blends. The product line offered by PharmaCann includes:

  • ZootDrops—Cannabis infused concentrates in Relaxation Blend and High-Energy Blend (100mg THC per bottle)
  • ZootBlast—Cannabis infused energy shots (available in 10mg and 30mg THC per bottle)
  • ZootChews—Cannabis infused gummies in Sour Apple, Wild Berry, Sour Lemonade and Watermelon (5mg THC each; 100mg THC per package—also available in CBD blends)

PharmaCann has Illinois dispensaries in Arlington Heights, Evanston, North Aurora, Ottawa and Romeoville, as well as an extensive wholesale network spanning the entire state. Each of PharmaCann’s dispensaries will offer Zoots Premium Cannabis Infused Edibles, with plans to roll out Zoots statewide through its wholesale partners.   Read this entire announcement  for IONC at:     https://www.financialnewsmedia.com/news-ionc/   

Additional industry related developments from around the markets:

Origin House (CSE: OH.CN) (OTCQX: ORHOF) recently announced that it has divested its 5.1% equity interest (the “Interest”) in Alternative Medical Enterprises LLC (“AltMed”) for total consideration of US$6 Million. As Cresco Labs Inc. (“Cresco”) is prohibited under state law from acquiring additional positions in the Florida market, this divestment was a pre-closing condition to the Company’s previously announced plan of arrangement (the “Arrangement”) pursuant to which Cresco has agreed to acquire all of the issued and outstanding shares of Origin House.

“With one of the final conditions to closing the Arrangement with Cresco now complete, we look forward to proceeding to drive value for shareholders as a combined company, upon the expiration of the anti-trust waiting period,” commented Marc Lustig, Chairman and CEO of Origin House. “The sale of the remaining AltMed interest marks a significant milestone in the continued process whereby Origin House has monetized non-core holdings resulting in both substantial returns for shareholders and additional cash that has fueled the Company’s growth.”

MedMen Enterprises Inc. (CSE: MMEN.CN) (OTCQX: MMNFF) recently announced that MedMen pre-roll singles and multipacks are available for purchase at its recently-opened West Palm Beach location. Available strains include “White Widow,” “Bubblegum OG,” and “Dr Who.”  To bring these products to the West Palm Beach community, the Company’s state-of-the-art cultivation and production facility located in the city of Eustis completed its first harvest of smokable flower in the state of Florida.

“Medical cannabis patients in Florida have fought long and hard to have smokable flower as an alternative for pain relief, and we are proud to offer them access to it,” said Adam Bierman, MedMen Co-Founder and CEO. “We look forward to continue working with regulators to bring safe, regulated and high-quality flower to other Florida communities where MedMen will operate in the future.”

Trulieve Cannabis Corp. (CSE: TRUL.CN) (OTCPK: TCNNF), a leading and top-performing cannabis company in the United States, recently announced the appointment of Peter T. Healy to its Board of Directors.  With continuing growth of the Company in Florida and the expansion of operations into new U.S. states, the addition of Peter Healy broadens the knowledge and experience base of Trulieve’s Board of Directors and further supports the execution of the Company’s strategic vision.

“We are very pleased to welcome Peter to the Trulieve Board,” said Kim Rivers, CEO of Trulieve. “Having advised a number of boards of public and private companies alike, and with a proven track record in financing, M&A, and cross-border listings, Trulieve will benefit from the unique knowledge and perspectives that Peter offers as we continue to bring high-quality products and an industry-leading customer experience to cannabis markets throughout the United States .”

Canopy Rivers Inc. (TSX-V: RIV) (OTCPK: CNPOF) recently announced that its 49%-owned joint venture, PharmHouse Inc.  (“PharmHouse”), has received a cultivation licence from Health Canada. PharmHouse will be immediately commencing operations in 190,000 sq. ft. of licensed nursery infrastructure and plans to ramp up the entire 1.3 million sq. ft. ultramodern greenhouse before the end of 2019 to deliver low-cost and high-quality cannabis and cannabis derivative products to the Canopy Rivers ecosystem of partners, both domestically and internationally.

“This is a significant corporate milestone for Canopy Rivers. We believe the PharmHouse platform to be the epitome of value creation for our shareholders, and exposure to this project represents an investment opportunity only available through Canopy Rivers,” said Narbe Alexandrian, President and CEO of Canopy Rivers”

 

DISCLAIMER:  FN Media Group LLC (FNM), which owns and operates FinancialNewsMedia.com and MarketNewsUpdates.com, is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels.  FNM is NOT affiliated in any manner with any company mentioned herein.  FNM and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security.  FNM’s market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities.  The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material.  All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks.  All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release.  FNM is not liable for any investment decisions by its readers or subscribers.  Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. For current services performed FNM has been compensated forty six hundred dollars for news coverage of the current press release issued above by IONIC Brands Corp. by a non affiliated third party.  FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNM undertakes no obligation to update such statements.

Wednesday, July 31st, 2019 Uncategorized Comments Off on $CNPOF $RIV Cannabis Edibles Market Projected to Quadruple in U.S. and Canada to $4.1 Billion

$BHAT Announces Closing of IPO

XIAMEN, China, July 31, 2019 via NetworkWire – Blue Hat Interactive Entertainment Technology (“Blue Hat”) (NASDAQ: BHAT), a producer, developer and operator of augmented reality interactive entertainment games and toys in China, announces the closing on July 30, 2019 of its underwritten initial public offering (“IPO”) of 2,000,000 ordinary shares priced at $4 per share, before underwriting discounts and commissions, resulting in gross proceeds of $8,000,000 before underwriting discounts and commissions and offering expenses. Blue Hat raised the proposed deal size from 1,800,000 shares as reflected in the original registration statement by filing an additional registration statement for the registration of additional shares to accommodate the upsizing. The offering was conducted on a firm commitment basis. All of the ordinary shares were offered by Blue Hat.

The ordinary shares were approved for listing on The Nasdaq Capital Market and on July 26, 2019, commenced trade under the ticker symbol “BHAT.”

ViewTrade Securities Inc. (“ViewTrade Securities”), a global provider of brokerage, investment banking, corporate, advisory and trading platform services, acted as the sole book-running manager and sole underwriter for the offering.

Blue Hat has granted ViewTrade Securities a 45-day option to purchase up to an additional 300,000 ordinary shares at the initial public offering price, less underwriting discounts and commissions, to cover over-allotments, if any.

A registration statement on Form F-1 (File No. 333-230051), including a prospectus relating to the offering, was filed with the U.S. Securities and Exchange Commission (the “SEC”) and on July 25, 2019, was declared effective by the SEC, and a registration statement filed pursuant to Rule 462(b) (File No. 333-232840) which increased the number of registered shares from 2,250,000 to 2,500,000 became effective upon filing with the SEC. The offering of the ordinary shares was made only by means of a prospectus. Copies of the final prospectus relating to the offering may be obtained on the SEC’s website (www.sec.gov) and may also be obtained from ViewTrade Securities Inc., Attention: Prospectus Department, 7280 W Palmetto Park Rd, Suite 310, Boca Raton, Florida 33433, or by email at ib@viewtrade.com. Please indicate your request for a prospectus.

Before you invest, you should read the prospectus and other documents Blue Hat has filed or will file with the SEC for more complete information about Blue Hat and the offering. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Blue Hat Interactive Entertainment Technology

Blue Hat, headquartered in Xiamen, China, is a producer, developer and operator of augmented reality interactive entertainment games and toys, including interactive educational materials, mobile games, and toys with mobile game features. For more information, visit the company’s website at www.bluehatgroup.net.

About ViewTrade Securities Inc.

ViewTrade Securities is a U.S.-registered broker dealer providing brokerage, trading, investment banking & advisory services for U.S. retail investors and B2B to major financial institutions worldwide, including some of the largest institutions in their domestic markets. ViewTrade Securities’ Investment Banking Division offers capital raising and advisory services to growth-oriented companies both domestically and in emerging markets.

Forward-Looking Statements

This press release contains certain forward-looking statements, including statements with regard to Blue Hat’s proposed initial public offering. Words such as “will,” future,” “expects,” “believes,” and “intends,” or similar expressions, are intended to identify forward-looking statements. Forward-looking statements are subject to inherent uncertainties in predicting future results and conditions and no assurance can be given that the proposed initial public offering discussed above will be completed on the terms described. Completion of the proposed initial public offering and the terms thereof are subject to numerous factors, many of which are beyond the control of Blue Hat, including, without limitation, the failure of customary closing conditions and the risk factors and other matters set forth in the prospectus included in the registration statement in the form last filed with the U.S. Securities and Exchange Commission. Blue Hat undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law.

Contacts

Blue Hat Contact
Blue Hat Interactive Entertainment Technology
Xiaodong Chen, President, Chief Executive Officer and Director
sean@bluehatgroup.net
86-592-228-0081

Corporate Communications  
Xiaoyun Zhang (张小云)
Corporate Communications
NetworkWire (NW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Xiaoyun.Zhang@NetworkWire.com

Wednesday, July 31st, 2019 Uncategorized Comments Off on $BHAT Announces Closing of IPO

$LXRP Summarizes DehydraTECH(TM) Technology Licensees

Biotechnology company and drug delivery platform innovator Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP) today reported on its existing technology licensees that have entered definitive contracts to use its revolutionary DehydraTECH(TM) absorption technology within their existing and emerging brands. “The first half of 2019 delivered a period of unprecedented achievements for Lexaria. We signed more license agreements than ever before in our Company’s history, many of which were larger in scope than anything previous,” Lexaria Chief Executive Officer Chris Bunka said in the news release. “We also launched our brand-new business division Lexaria Nicotine which is disrupting nicotine delivery methods that already attracted one of the world’s largest nicotine companies, which has licensed our technology.”

To view the full press release, visit: http://nnw.fm/go6Et

About Lexaria Bioscience Corp.

Lexaria Bioscience Corp. licenses disruptive, patented-delivery technology that promotes healthier ingestion methods, lower overall dosing and higher effectiveness of lipophilic active molecules. Lexaria has multiple patents pending in over 40 countries around the world and has patents granted in the United States and Australia for utilization of its DehydraTECH delivery technology. Lexaria’s technology provides increases in intestinal absorption rates, more rapid delivery to the bloodstream, and important taste-masking benefits for orally administered bioactive molecules including cannabinoids, vitamins, nonsteroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules. For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LXRP are available in the company’s newsroom at http://nnw.fm/LXRP

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive instant SMS alerts, text STOCKS to 77948

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

Tuesday, July 30th, 2019 Uncategorized Comments Off on $LXRP Summarizes DehydraTECH(TM) Technology Licensees

$GGBXF Posts Updated Terms to Spring Oaks Acquisition

Green Growth Brands (CSE: GGB) (OTCQB: GGBXF), a lifestyle-oriented cannabis company, on Monday announced an amendment to the share purchase agreement dated June 3, 2019 with Spring Oaks Greenhouses, Inc. Per the amended agreement, GGBXF will acquire all of the issued and outstanding shares of capital stock of Spring Oaks. According to the amendment, the purchase price of $54,650,000 will be comprised of a previously paid deposit of $1,350,000; a cash payment of $2,000,000 at closing, subject to certain adjustments acknowledged in the agreement; a cash payment of $3,000,000 due on August 31, 2019; the issuance of 7,133,297 common shares of GGBXF to the owners of Spring Oaks representing a total of $17,100,000 at a price of $2.39 each; the issuance of 8,094,210 additional common shares to the owners of Spring Oaks representing a total of $14,000,000, at a price of $1.72 each; the issuance of a two-year convertible secured promissory note in the aggregate principal amount of $11,400,000 that will bear interest at a rate of 15%, payable after the first year, and with a 24 month maturity date from closing and a conversion rate equal to $2.39; and the issuance of a one-year convertible secured promissory note in the aggregate principal amount of $5,800,000. The one-year note will bear interest at a rate of 15%, simple interest, per annum, and has a maturity date of 12 months following the date of closing. At the option of Spring Oaks, the one-year note is convertible on the maturity date into common shares of GGBXF at a conversion rate of $1.72. The shares issued as part of the purchase price are subject to a lock-up agreement for 20 months following the date of closing, to be released in increments of 1/20 over that time period. In addition, GGBXF will pay a fee of $500,000 to Jeremy Giles in connection with the anticipated closing. The fee will be comprised of a cash payment in the amount of $250,000 and the issuance of common shares totaling $250,000, priced at $1.72 each. GGBXF and Giles are expected to enter into a consulting services agreement for governmental relations services.

To view the full press release, visit: http://nnw.fm/g4ZqJ

About Green Growth Brands

Green Growth Brands creates remarkable experiences in cannabis and CBD. Led by CEO Peter Horvath and a leadership team of consumer-focused retail experts, the company’s brands include CAMP, Seventh Sense Botanical Therapy, The+Source, Green Lily, and Meri + Jayne. The company also has a licensing agreement with the Greg Norman(TM) Brand to develop a line of CBD-infused personal care products designed for active wellness. Already driving the strongest sales per square feet in the cannabis industry, GGB is expanding its cannabis operations throughout the U.S., its CBD presence at ShopSeventhSense.com, in malls across the country and at DSW shoe stores—and that’s just the beginning. For more information, visit the company’s website at www.GreenGrowthBrands.com.

NOTE TO INVESTORS: The latest news and updates relating to GGBXF are available in the company’s newsroom at http://nnw.fm/GGBXF

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive instant SMS alerts, text STOCKS to 77948

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

Tuesday, July 30th, 2019 Uncategorized Comments Off on $GGBXF Posts Updated Terms to Spring Oaks Acquisition

$PBIO Bold Entry into CBD Market with Next-Gen Nanoemulsification Platform

  • PBIO’s proprietary Ultra Shear Technology (UST) platform achieves the long sought-after ability to create truly water-soluble CBD oil that can provide optimized bioavailability
  • CBD sales are projected to reach $89 billion by 2024 with a CAGR of 37 percent (2018-2024 forecast period)
  • Analysts predict that the biggest short-term challenge for CBD businesses will be oversaturation and stiff competition in the marketplace; companies producing the highest-quality, most bioavailable CBD products are expected to earn top customer loyalty

Finding success in the lucrative yet ultra-competitive CBD industry is a daunting challenge for businesses in the space, with oversaturation in the marketplace being a real concern. The cannabis market was valued at $14.5 billion in 2018 and is projected to reach $89.1 billion by 2024, with a compound annual growth rate of 37 percent during the forecast period, according to Mordor Intelligence (http://nnw.fm/fR3cA). CBD manufacturers may find tapping into this booming trend to be short-lived if their CBD offerings don’t stand up to consumers’ expectations that the products they purchase are as beneficial as advertised.

Pressure BioSciences Inc. (OTCQB: PBIO), a leader in the development and sale of high pressure-based instruments, consumables and related services for the global life sciences and other industries, has developed a novel, proprietary process that has…

Read more »

NOTE TO INVESTORS: The latest news and updates relating to PBIO are available in the company’s newsroom at http://nnw.fm/PBIO

 

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive instant SMS alerts, text STOCKS to 77948

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

Tuesday, July 30th, 2019 Uncategorized Comments Off on $PBIO Bold Entry into CBD Market with Next-Gen Nanoemulsification Platform

$OGI Five of the Top Hemp Stocks to Watch in 2019

Palm Beach, FL – July 30, 2019 – With the passage of the Farm Bill, hemp will see a significant catalyst for growth. It could see even more growth once the U.S. Department of Agriculture (USDA) introduces federal hemp rules in August 2019, speeding previous plans to roll out the guidelines by 2020.  Along the way, it may just create a $39.4 billion market, says Markets and Markets, strong growth from a $10.3 billion valuation in 2018.  That’s opening a wide range of opportunity for companies including MYM Nutraceuticals Inc. (OTCQB:MYMMF) (CSE:MYM), OrganiGram Holdings Inc. (NASDAQ:OGI) (TSX-V:OGI), Aurora Cannabis Inc. (NYSE:ACB)(TSX:ACB), CannTrust Holdings Inc. (NYSE:CTST), (TSX:TRST) and PharmaCielo Ltd. (OTCPK:PHCEF) (TSX-V:PCLO).

MYM Nutraceuticals Inc. (CSE:MYM)(OTCQB:MYMMF) BREAKING NEWS: MYM Nutraceuticals just announced it has finalized the acquisition of 50% of BioHemp Naturals, a licensed hemp cultivator in the business of cultivating and distributing CBD-rich hemp biomass to licensed producers in Canada. BioHemp co-founder, Len Atkinson, has joined the MYM management team as Global Hemp Project Manager.  BioHemp’s founder has been growing hemp since 2015 and developed unique harvesting methods and standard operating procedures which meet all Health Canada testing requirements for hemp. BioHemp is expanding its hemp operations to cultivate 450 acres this 2019 season. Working with BioHemp, MYM is hoping to expand cultivation to 3,000 acres of CBD-rich hemp for the 2020 grow season. To date, MYM and BioHemp have purchase agreements in place totaling over $33 million.

“Finalizing the acquisition of 50% of BioHemp Naturals and engaging Mr. Atkinson as MYM’s Global Hemp Project Manager is another positive move in the restructuring of MYM to become a global player in the cultivation, extraction, and distribution of CBD-rich hemp,” said Howard Steinberg, CEO of MYM.  In exchange for 50% of BioHemp Naturals, MYM will pay a total of $2.5 million cash (in two tranches) and 6,000,000 common shares in the capital of MYM.  For more information on MYM, please visit:  https://www.mym.ca/

 

Other cannabis-related developments from around the markets include:

OrganiGram Holdings Inc. (TSXV:OGI) (NASDAQ:OGI) just announced its financial results for the third quarter ended May 31, 2019.  “We continued to report strong sales in our third quarter and now have distribution in all ten provinces. In our fiscal year to date, we have generated strong operating and financial results, placing us among the leaders in the Canadian industry. While we saw a temporary reduction in yield per plant in Q3 due to temporary changes in growing protocols, not only have our yields returned to historical levels, but we have seen a meaningful increase in average cannabinoid levels in harvests to date in Q4” said Greg Engel, Chief Executive Officer. “We have seen adult recreational cannabis sales highly correlate to the presence of physical retail stores based on a comparison of the provinces in Canada. The Canadian market is positioned to grow significantly with more retail stores opening – particularly in the two most populous provinces of Ontario and Quebec – and the upcoming legalization and availability of edibles and derivative products.”

“We expect to remain a national market leader by maintaining our track record of meeting supply commitments and delivering high-quality product to our customers. Our experienced team continues to de-risk our edibles and derivative strategy in order to be ready to launch the most popular cannabis product forms upon legalization. We are very excited for fiscal 2020 which should build upon an already successful 2019. By the first half of fiscal 2020, we expect to benefit from record harvests of high-quality indoor-grown dried flower, the sale of a variety of vape pen products as well as our initial edible product forms. The Canadian market will be much more mature from a distribution and retail perspective with Ontario anticipated to have three-times the current number of stores by October 2019 and Quebec planning to more than double its retail presence by March 2020 and with Alberta continuing to grow its already leading number of retail distribution points.”

Aurora Cannabis Inc. (NYSE:ACB) (TSX:ACB) just received Health Canada licenses for outdoor cultivation at two Canadian sites. The new sites in Quebec and British Columbia will be used for cultivation research to develop new technology, genetics and intellectual property in order to drive sustainable, high-quality outdoor production. Aurora purposefully chose the outdoor sites because they represent two different growing environments. The company will conduct research on cultivation techniques to further excel at growing cannabis in varying climate conditions and will examine approaches to environmentally sustainable cannabis agriculture. The newly-named Western facility will be called Aurora Valley and is a 207-acre operation in Westwold, British Columbia. The Eastern facility, a 21,000 square foot operation at the Aurora Eau facility in Lachute, is the first approved outdoor grow operation for cannabis in Quebec. Aurora Valley is expected to be planted shortly and Aurora Eau has already been planted.

The two sites are an extension of the scientific research Aurora will be conducting at its new Comox facility, which will be ready in the fall of 2019. The Comox facility consists of a 21,000 square foot indoor grow facility and a 10,500 square foot laboratory. This unique research centre will be home for Aurora’s plant breeding team designed to create new cannabis cultivars with improved growing characteristics for both indoor and outdoor cultivation. “Aurora believes in innovative operations and intensive research and we’re applying our approach to outdoor grown cannabis,” said Aurora CEO Terry Booth. “Our team plans to use these areas to ensure we are able to consistently grow the high-quality cannabis Aurora has become known for around the world. We’re proud to be a Canadian company and this is a further commitment to research and job creation in Canada.”

CannTrust Holdings Inc. (TSX:TRST)(NYSE:CTST) just announced immediate senior management changes and other interim actions based on the ongoing investigation being undertaken by a special committee of its board of directors. The investigation into the Company’s non-compliance with Health Canada regulations and ancillary matters uncovered new information that has resulted in a determination by the Board to terminate with cause CannTrust CEO Peter Aceto.  In addition, the Board of Directors demanded the resignation of the Company’s Chair Eric Paul and he complied.  Effective immediately, the Board has appointed Special Committee Chair Robert Marcovitch to the role of interim CEO and he will step down as a member of the Special Committee. “Our first priority is to complete the remaining items of our investigation and bring the Company’s operations into full regulatory compliance.  Implementing the necessary changes is essential to the interests of our medical patients, customers, shareholders and employees,” said Mr. Marcovitch. “CannTrust has a number of strengths it can draw upon to reset and rebuild, including industry-leading research, innovation and intellectual property.”

PharmaCielo Ltd. (TSXV:PCLO)(OTCPK:PHCEF) announced that it has completed the necessary permitting process required to enable Colombia’s first commercial export and sale of non-psychoactive (CBD) isolate.  The extensive process fulfils the extensive and final regulatory obligations required, including individual approvals by the Colombian Ministries of Health and Justice, in order to commence product exportation.  With this prerequisite accomplished, the Company will begin the process of confirming a series of international business relationships and configuring inaugural commercial shipments of high-grade medicinal CBD isolate, with a purity certificate of analysis (COA) of 99+% and meeting all other strict quality control standard requirements established by the Colombian government.  “Enabling product delivery to customers is one of the most exciting and memorable moments for any company, and we are thrilled about this accomplishment,” said David Attard, CEO of PharmaCielo Ltd. “This specific point in time not only distills the vision, hard work, dedication and commitment of our team, but also signifies the transition of PharmaCielo from a founding stage into a mature company with the infrastructure of production, distribution and sales operations that can deliver high-quality products to its clients.”

DISCLAIMER:  FN Media Group LLC (FNM), which owns and operates Financialnewsmedia.com and MarketNewsUpdates.com, is a third- party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels.  FNM is NOT affiliated in any manner with any company mentioned herein.  FNM and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security.  FNM’s market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities.  The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material.  All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks.  All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release.  FNM is not liable for any investment decisions by its readers or subscribers.  Investors are cautioned that they may lose all or a portion of their investment when investing in stocks.  For current services performed FNM expects to be compensated twenty-five hundred dollars for news coverage of the current press release issued by MYM Nutraceuticals Inc. by a non-affiliated third party.  FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNM undertakes no obligation to update such statements.

Tuesday, July 30th, 2019 Uncategorized Comments Off on $OGI Five of the Top Hemp Stocks to Watch in 2019

$GGBXF Announces Updated Terms Related To Its Acquisition Of Florida-Based Spring Oaks

COLUMBUS, OH, July 29, 2019  – Green Growth Brands, Inc. (CSE: GGB) (OTCQB: GGBXF) (“GGB” or “the Company”) today announced that it has executed an amendment (the “Amendment”) to the Share Purchase Agreement  (the “Agreement”), dated June 3, 2019, with Spring Oaks Greenhouses, Inc. (“Spring Oaks”), pursuant to which GGB is to acquire all of the issued and outstanding shares of capital stock of Spring Oaks.

Pursuant to the Amendment, the purchase price for the shares of capital stock of Spring Oaks of US$54,650,000 (C$72,039,630), subject to certain post-closing purchase price adjustments, shall be satisfied by GGB at closing through a combination of: (i) a previously paid deposit of US$1,350,000 (C$1,779,570); (ii) a cash payment at closing of US$2,000,000 (C$2,636,400), subject to certain adjustments identified in the Agreement; (iii) a cash payment of US$3,000,000 (C$3,954,600) due on August 31, 2019; (iv) the issuance of 7,133,297 common shares of GGB (the “Consideration Shares”) to the owners of Spring Oaks representing an aggregate amount of US$17,100,000 (C$22,541,220) at a price of US$2.39 (C$3.16) per Consideration Shares; (v) the issuance of 8,094,210 common shares of GGB (the “Additional Consideration Shares”) to the owners of Spring Oaks representing an aggregate amount of US$14,000,000 (C$18,454,800), at a price of US$1.72 (C$2.28) per Additional Consideration Shares; (vi) the issuance of a two-year convertible secured promissory note in the aggregate principal amount of US$11,400,000 (C$15,027480) (the “Two-Year Note”); and (vii) the issuance of a one-year convertible secured promissory note in the aggregate principal amount of US$5,800,000 (C$7,645,560) (the “One-Year Note”).

The Two-Year Note shall bear interest at a rate of 15%, payable after the first year, and shall have a maturity date of 24 months following the date of closing.  The Two-Year Note shall be convertible, on the maturity date, at the option of Spring Oaks, into common shares of GGB at a conversion rate equal to US$2.39 (C$3.16) and shall be secured by the Spring Oaks assets. The One-Year Note shall bear interest at a rate of 15%, simple interest, per annum, and shall have a maturity date of 12 months following the date of closing.  The One-Year Note shall be convertible, on the maturity date, at the option of Spring Oaks, into common shares of GGB at a conversion rate of  US$1.72 (C$2.28), representing the closing market price of a GGB common share on the CSE on the trading day immediately prior the date hereof.  The One Year Note shall be secured by the Spring Oaks assets.  Both the Consideration Shares and the Additional Consideration Shares shall be subject to a lock-up agreement for 20 months following the date of closing, to be released in increments of 1/20 over that time period.

In connection with the anticipated closing, GGB will pay a fee (the “Fee”) of US$500,000 (C$659,100) to Jeremy Giles in full satisfaction and settlement of certain finder services performed on GGB’s behalf.  The Fee will be paid through (1) a cash payment in the amount of US$250,000 (C$329,550) and (2)  the issuance of common shares of GGB in the aggregate amount of US$250,000 (C$329,550), priced at US$1.72 (C$2.28), representing the closing market price of a GGB common share on the CSE on the trading day immediately prior to the date of this announcement. GGB will also enter into a Consulting Services Agreement with Mr. Giles for governmental relations services.

About Green Growth Brands Inc.
Green Growth Brands creates remarkable experiences in cannabis and CBD. Led by CEO Peter Horvath and a leadership team of consumer-focused retail experts, the company’s brands include CAMP, Seventh Sense Botanical Therapy, The+Source, Green Lily, and Meri + Jayne. The Company also has a licensing agreement with the Greg Norman™ Brand to develop a line of CBD-infused personal care products designed for active wellness. Already driving the strongest sales per square feet in the cannabis industry, GGB is expanding its cannabis operations throughout the U.S., its CBD presence at ShopSeventhSense.com, in malls across the country and at DSW shoe stores—and that’s just the beginning. Learn more about our vision at GreenGrowthBrands.com.

Cautionary Statements:

Certain information in this news release constitutes forward-looking statements under applicable securities law. Any statements that are contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements are often identified by terms such as “may”, “should”, “anticipate”, “expect”, “intend”, “forecast” and similar expressions.  Forward-looking statements necessarily involve known and unknown risks, including, without limitation, risks associated with general economic conditions; adverse industry events; marketing costs; loss of markets; future legislative and regulatory developments involving medical and recreational marijuana; inability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favorable terms; the marijuana industry in the United States, income tax and regulatory matters; the ability of the Company to implement its business strategies; competition; currency and interest rate fluctuations and other risks, including those factors described under the heading “Risks Factors” in the Company’s Annual Information Form dated November 26, 2018 which is available on the Company’s issuer profile on SEDAR.

Readers are cautioned that the foregoing list is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking statements as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. The forward-looking statements contained in this release, including, but not limited to, the Company’s ability to execute on its growth strategy, the Company’s vision to become a multi-state operator with retail stores exceeding certain financial thresholds, is made as of the date hereof and the Company is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement.

This announcement does not constitute an offer, invitation or recommendation to subscribe for or purchase any securities and neither this announcement nor anything contained in it shall form the basis of any contract or commitment. In particular, this announcement does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States, or in any other jurisdiction in which such an offer would be illegal.

The securities referred to herein have not been and will not be registered under the Securities Act of 1933, as amended (the “Securities Act”), or under the securities laws of any state or other jurisdiction of the United States and may not be offered or sold, directly or indirectly, within the United States, unless the securities have been registered under the Securities Act or an exemption from the registration requirements of the Securities Act is available.

Monday, July 29th, 2019 Uncategorized Comments Off on $GGBXF Announces Updated Terms Related To Its Acquisition Of Florida-Based Spring Oaks

$INMB Research Highlights Strategy in Fighting Cancer with Body’s Own Natural Cells

  • California-based INmune Bio is developing therapies to battle cancers and Alzheimer’s disease by more effectively engaging the body’s own natural defenses
  • Research published in a peer-reviewed scientific journal shows a mechanism by which scientists can track and strategize natural killer cell promotion as an innate physical response to cancer in lieu of other pharmaceutical inducements
  • INmune Bio’s INKmune product, derived from the cell line used in its research, naturally targets “residual disease” cells that may survive other cancer treatments and revitalize themselves to create a relapse of cancer

The battle to marshal naturally occurring cells within the human body to destroy cancerous tumors has gained new intelligence that appears to strengthen an immunotherapy strategy employed by clinical-stage biotechnology company INmune Bio Inc. (NASDAQ: INMB). The encouraging report arises from research on tumor-primed vs. cytokine-primed human natural killer (NK) cells, published in June in peer-reviewed, open-access scientific journal PLOS ONE (http://nnw.fm/5yNeD).

“We are delighted to be sharing these data describing the unique molecular pathways triggered within human NK cells upon priming with INmune Bio’s own INB16 (INKmune) cell line,” INmune Bio co-founder and Chief Scientific Officer Dr. Mark Lowdell, who co-authored the…

Read more »

NOTE TO INVESTORS: The latest news and updates relating to INMB are available in the company’s newsroom at http://nnw.fm/INMB

 

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive instant SMS alerts, text STOCKS to 77948

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

Monday, July 29th, 2019 Uncategorized Comments Off on $INMB Research Highlights Strategy in Fighting Cancer with Body’s Own Natural Cells

$TGODF Global CBD Sales Expected to Grow to $22 billion by 2022

Palm Beach, FL – July 29, 2019 – It’s no secret the cannabis market is booming globally.  By 2023, The Marijuana Business Factbook projects that total retail cannabis sales in the U.S. could reach between $25 billion and $30 billion annually.  In addition, according to the Brightfield Group, worldwide CBD sales are expected to soar from $591 million in 2018 to as high as $22 billion by 2022 – a compound growth rate of 147%.  Better, many more Americans are becoming very comfortable with cannabis and CBD legalization, which could fuel a sizable, multi-year boom.  That’s opening a wide range of opportunity for companies including Naturally Splendid Enterprises Ltd. (TSX-V:NSP)(OTCQB:NSPDF), Charlotte’s Web Holdings Inc. (CSE:CWEB)(OTCQX:CWBHF), The Green Organic Dutchman Holdings Ltd. (TSX:TGOD) (OTCQX:TGODF), Aphria Inc. (NYSE:APHA)(TSX:APHA), and Canopy Growth Corporation (NYSE:CGC)(TSX :WEED).

Naturally Splendid Enterprises Ltd. (TSX-V:NSP)(OTCQB:NSPDF) BREAKING NEWS: Naturally Splendid Enterprises Ltd. just announced the most recent upgrades to the Company’s manufacturing and distribution facility are completed and the designation of Safe Quality Food (SQF) Level 2 Certification has been successfully attained. Earlier, the Company announced being ‘SQF Level 2 Compliant’ while awaiting on-site, independent, third-party evaluation. Naturally Splendid is pleased to now report, that after passing their independent, on site third-party audit, the Company has reached the prestigious designation of Safe Quality Food Level 2 Certification. In 2018, the Company allocated essential investment capital to acquire additional manufacturing equipment to upgrade its facility to SQF Level 2 Certification and build an R&D test kitchen, thus expanding production capabilities. The purpose of securing SQF Level 2 Certification links directly to the expanded opportunities afforded the Company that unaccredited facilities are not compliant to produce for.

Naturally Splendid Executive VP of Operations Mr. Bryan Carson reports, “Attaining SQF Level 2 Certification announces to the food industry, that Naturally Splendid has invested in the necessary infrastructure to ensure our clients are receiving the best and safest products possible. We are already benefitting from attaining this certification by attracting additional contract manufacturing clients and are now manufacturing seven days a week at our facility with plans to add a second shift to keep up with purchase orders.”

Other cannabis-related developments from around the markets include:

 

Charlotte’s Web Holdings Inc. (CSE:CWEB)(OTCQX:CWBHF) entered into a research initiative with Rodale Institute and Natural Care to pioneer regenerative organic hemp farming. The research will be conducted at Pocono Organics, a start-up regenerative organic farm in Long Pond, Pennsylvania.  In alignment with its corporate social responsibility values, Charlotte’s Web has been active in responsible farming practices since 2016. As people become increasingly aware of the benefits of organic and regenerative agriculture for their own health and the health of the planet, Charlotte’s Web is partnering with Rodale Institute, the global leader in regenerative organic agriculture, to advance the development of healthy agriculture practices for the burgeoning hemp industry. Natural Care, one of the largest and only regenerative organic hemp research and cultivation operations in the country, is funding the multi-year research initiative.  In collaboration with Rodale Institute, Natural Care will oversee and host the research at the Pocono Organics farm. “We’re very proud to be an active partner supporting this research, which aims to bring regenerative agriculture to hemp in this region of the country, through our collaboration with Rodale Institute, Natural Care, and Pocono Organics,” said Deanie Elsner, CEO of Charlotte’s Web. “As the industry leader, Charlotte’s Web aims to continually raise the bar for responsible hemp farming practices. It is our intent that the data from this research will support furthering sustainability for hemp farming.”

The Green Organic Dutchman Holdings Ltd. (TSX:TGOD) (OTCQX:TGODF) announced that its flagship Valleyfield, QC facility has received its organic certification from Pro-Cert, an internationally recognized leader in organic certification. Once completed, TGOD’s Valleyfield facility is going to be the world’s largest organic cannabis facility at over 1.3 million square feet. This Pro-Cert recognition adds another certification to the Company’s portfolio, in addition to TGOD’s already certified organic growing facilities in Canada and Europe, and shows TGOD’s commitment to cement its position as the leading organic cannabis brand globally.  “It’s exciting to reach new milestones as we begin commercial production. Growing certified organic cannabis at scale is a highly complex process which has taken time, great care and extensive research to refine. Each of our facilities goes through a robust certification process, in line with the high standards we have set, ensuring operational excellence at all stages,” commented Brian Athaide, CEO of TGOD. “The proprietary methods our team has developed leverage the benefits of growing in living soil and guarantees the organic integrity of the products throughout the entire production chain.”

Aphria Inc. (NYSE:APHA)(TSX:APHA) announced the launch of its new social impact platform, Plant Positivity. Championing the incredible power that plants have in overall well-being and providing greater access to green spaces for communities, Plant Positivity will be a new component of Aphria’s existing Corporate Social Responsibility strategy, which will continue to deliver on the Company’s commitment to give back to both people and the planet. The platform will be brought to life through three interconnected pillars – Plant Education, Plant Access, and Plant Impact.  In 2019, Plant Positivity is partnering with the national not-for-profit Evergreen to create six new garden spaces this summer – the Plant Positivity Gardens – at the national headquarters, Evergreen Brick Works in Toronto. Aphria’s investment will add more than 50 varieties of native plant species to the existing 8,000-square-metres of gardens across the site, a global showcase for sustainability and urban innovation that opened in 2010. Plans are also underway to develop a Plant Positivity Garden in Leamington, Ontario with a local community partner.  “Finding ways to give back and fostering stronger, healthier communities everywhere Aphria operates is the core of who we are,” said Irwin D. Simon, Interim CEO, Aphria Inc. “Countless studies have shown that increased exposure to plants and green spaces contributes to overall well-being. Through our Plant Positivity Gardens at the Evergreen Brick Works, we hope to make a meaningful impact on people’s lives.”

Canopy Growth Corporation (NYSE:CGC)(TSX :WEED) will publicly unveil its Hemp Industrial Park on Pine Camp Drive in Kirkwood, Broome County on Monday, July 29th at 10:30 AM. To mark the occasion, we are hosting an event with Canopy Growth executives and Government Officials.  Media are invited to join Canopy Growth President Rade Kovacevic, Canopy Growth Chief Advocacy Officer Hilary Black, Senate Minority Leader Chuck Schumer (NY), Department of Agriculture and Markets Commissioner, Richard Ball (NY), New York State Senator Fred Akshar, State Assemblywoman Donna Lupardo, Broome County Executive Jason Garnar, Kirkwood Town Supervisor Gordon Kniffen, and a representative from Congressman Brindisi’s staff as they deliver remarks and take questions from media and guests.

DISCLAIMER:  FN Media Group LLC (FNM), which owns and operates Financialnewsmedia.com and MarketNewsUpdates.com, is a third- party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels.  FNM is NOT affiliated in any manner with any company mentioned herein.  FNM and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security.  FNM’s market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities.  The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material.  All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks.  All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release.  FNM is not liable for any investment decisions by its readers or subscribers.  Investors are cautioned that they may lose all or a portion of their investment when investing in stocks.  For current services performed FNM expects to be compensated twenty-five hundred dollars for news coverage of the current press release issued by Naturally Splendid Enterprises Ltd. by a non-affiliated third party.  FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNM undertakes no obligation to update such statements.

Monday, July 29th, 2019 Uncategorized Comments Off on $TGODF Global CBD Sales Expected to Grow to $22 billion by 2022

$OGI Increases Licensed Production Capacity

Organigram Holdings (TSX.V: OGI) (NASDAQ: OGI), parent company of Organigram Inc., a leading licensed producer of cannabis, recently obtained approval from Health Canada for the licensing of all of the company’s Phase 4A buildout plans, increasing its total licensed production capacity to 61,000 kg. per year (http://nnw.fm/30Wgt). An article discussing the company reads, “Once fully licensed and operational, the full Phase 4 expansion is expected to bring the company’s annualized target production capacity to approximately 113,000 kg. of dried-flower equivalents. . . . ‘Organigram’s continued expansion reflects ongoing growth in the cannabis marketplace, including increasing demand as new retail stores come online in Alberta, Ontario, Quebec and British Columbia,’ CEO Greg Engel said in a news release. ‘The expansion of our facility and production capacity will help ensure we have additional product for extraction for the launch of the edibles and derivatives market before the end of 2019.’”

To view the full article, visit: http://nnw.fm/oU6Bt

About Organigram Holdings Inc.

Organigram Holdings is a TSX Venture Exchange- and NASDAQ Global Select-listed company whose wholly owned subsidiary, Organigram Inc., is a licensed producer of cannabis and cannabis-derived products in Canada. Organigram is focused on producing the highest-quality, indoor-grown cannabis for patients and adult-recreational consumers in Canada, as well as developing international business partnerships to extend the company’s global footprint. Organigram has also developed a portfolio of legal adult-use recreational cannabis brands including the Edison Cannabis Company, Ankr Organics, Trailer Park Buds and Trailblazer. Organigram’s primary facility is located in Moncton, New Brunswick, and the company is regulated by the Cannabis Act and the Cannabis Regulations (Canada). For more information, visit the company’s website at www.Organigram.ca.

NOTE TO INVESTORS: The latest news and updates relating to OGI are available in the company’s newsroom at http://nnw.fm/OGRMF

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive instant SMS alerts, text STOCKS to 77948

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

Monday, July 29th, 2019 Uncategorized Comments Off on $OGI Increases Licensed Production Capacity

$TGODF Upholds Commitment to Quality amid CBD Shortage

The Green Organic Dutchman Holdings (TSX: TGOD) (OTCQX: TGODF), a cannabis-focused research and development company, remains dedicated to maintaining its high standards in the midst of a growing cannabis supply gap. An article discussing the company reads, “TGOD is one of three organic cannabis growers in Canada. No synthetic pesticides or fertilizers are used in the company’s growing process. The company is also dedicated to creating a smaller environmental footprint by using less water and energy, low-cost power solutions and smarter efficient packaging. By growing organically and at low costs, TGOD’s final product demands a premium in the market, thereby increasing margins. . . . In April, Marijuana Business Daily reported that Canadian cannabis wholesalers are reporting a CBD shortage (http://nnw.fm/16c4M). The demand for product has been higher than expected, and companies such as TGOD are working to ensure that the gap is filled, without sacrificing on quality standards. Certified organic by North America’s most-recognized organic certification bodies — Pro-Cert and ECOCERT Canada — TGOD stands by the slower, more sustainable methods of growing, believing them to be the best way to provide consumers with the premium products they deserve.”

To view the full article, visit: http://nnw.fm/sKjH2

About the Green Organic Dutchman Holdings Ltd.

The Green Organic Dutchman Holdings is a publicly traded, premium, global, organic-cannabis company with operations focused on medical-cannabis markets in Canada, Europe, the Caribbean and Latin America, as well as the Canadian adult-use market. TGOD also has organic-hemp, CBD-oil operations in Canada and, through its wholly owned subsidiary HemPoland, distributes premium-hemp CBD oil in the European Union. The company grows high-quality, organic cannabis with sustainable, all-natural principles. TGOD’s products are laboratory tested to ensure patients have access to a standardized, safe, consistent product. TGOD has a planned capacity of 219,000 kgs. and is building 1,643,600 square feet of cultivation and processing facilities across Ontario, Quebec, Jamaica and Denmark. For more information, visit the company’s website at www.TGOD.ca.

NOTE TO INVESTORS: The latest news and updates relating to TGODF are available in the company’s newsroom at http://nnw.fm/TGODF

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive instant SMS alerts, text STOCKS to 77948

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

Friday, July 26th, 2019 Uncategorized Comments Off on $TGODF Upholds Commitment to Quality amid CBD Shortage

$OGI Signs New Agreement for Access to 60,000kg of CBD-rich Hemp

  • New advance purchase agreement with 1812 Hemp for access to as much as 60,000kg of hemp flower to be harvested in calendar 2019
  • Organigram maintains right of first refusal on 1812 Hemp’s future harvests
  • In 2018 Organigram purchased 4,300 kg of hemp flower from 1812 Hemp with exceptional levels of CBD which has been extracted into isolate and is being formulated for medical and recreational sale

Organigram Holdings Inc. (NASDAQ Global Select; TSX-V: OGI) the parent company of Organigram Inc. (collectively the “Company” or “Organigram”), a leading licensed producer of cannabis, is pleased to announce that it has entered into an advance payment and purchase agreement (the “Payment Agreement”) with 703454 N.B. Inc. (carrying on business as 1812 Hemp) (“1812 Hemp”) under which the Company will pre-fund hemp purchases to receive access to as much as 60,000 kilograms of dried hemp flower to be harvested in calendar 2019 for extraction into cannabidiol (“CBD”) isolate.

Organigram is already a party to a purchase agreement entered into in January 2019 with 1812 Hemp (the “January Purchase Agreement”), in which Organigram was granted a right of first refusal on 1812 Hemp’s production of certain hemp cultivars.

Access to CBD-rich hemp flower is being facilitated through the Payment Agreement as the Company will advance funds to 1812 Hemp for their purchase of specialized large-scale hemp harvesting and processing equipment to maximize crop yields, contribute to increased efficiency and improve preservation of harvested cannabinoids. Purchase conditions for the dried hemp flower continue to be governed by the January Purchase Agreement which secures supply and supports research and development on the genetic improvement of hemp through traditional plant breeding methods. Funds advanced by Organigram will be credited toward future hemp flower purchases under the January Purchase Agreement.

Under the terms of the January Purchase Agreement, Organigram obtained access to a supply of hemp flower which contains significant and exceptional levels of CBD, as compared to other Health Canada-approved cultivars currently in commercial production in Canada. CBD is a naturally occurring active ingredient in hemp and cannabis that is currently being studied for various therapeutic uses.

“Access to a large, consistent volume of CBD-producing hemp has become increasingly important as Canadians express their demand for CBD-rich products for use in both recreational and medical capacities,” said Greg Engel, CEO, Organigram. “We’ve heard the call for CBD in the market and this agreement positions Organigram to meet that demand.”

About 1812 Hemp

1812 Hemp is a New Brunswick based industrial hemp company focused on furthering the genetic development of existing, and new hemp cultivars for various applications including natural products, fibres and medicinal products. For more information, visit 1812hemp.ca.

About Organigram Holdings Inc.

Organigram Holdings Inc. is a NASDAQ Global Select and TSX Venture Exchange listed company whose wholly owned subsidiary, Organigram Inc., is a licensed producer of cannabis and cannabis-derived products in Canada.

Organigram is focused on producing high-quality, indoor-grown cannabis for patients and adult recreational consumers in Canada, as well as developing international business partnerships to extend the company’s global footprint. Organigram has also developed a portfolio of legal adult use recreational cannabis brands including The Edison Cannabis Company, Ankr Organics, Trailer Park Buds and Trailblazer. Organigram’s primary facility is located in Moncton, New Brunswick and the Company is regulated by the Cannabis Act and the Cannabis Regulations (Canada).

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This news release contains forward-looking information. Often, but not always, forward-looking information can be identified by the use of words such as “plans”, “expects”, “estimates”, “intends”, “anticipates”, “believes” or variations of such words and phrases or state that certain actions, events, or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Forward-looking information involves known and unknown risks, uncertainties and other factors that may cause actual results, events, performance or achievements of Organigram to differ materially from current expectations or future results, performance or achievements expressed or implied by the forward-looking information contained in this news release. Examples of such statements include statements with respect to quantities and quality of CBD to be purchased and processed, processing and commercialization. Risks, uncertainties and other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information including results of harvests and as disclosed in the Company’s most recent annual information form and other Company’s documents filed from time to time under the Company’s issuer profile on the Canadian Securities Administrators’ System for Electronic Document Analysis and Retrieval (“SEDAR”) at www.sedar.com and reports and other information filed with or furnished to the United States Securities and Exchange Commission (“SEC”) and available on the SEC’s Electronic Document Gathering and Retrieval System (“EDGAR”) at www.sec.gov. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Although the Company believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information and no assurance can be given that such events will occur in the disclosed time frames or at all. The forward-looking information included in this news release are made as of the date of this news release and the Company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking information, whether as a result of new information, future events or otherwise. We seek safe harbor.

For Investor Relations enquiries:
Amy Schwalm
Vice President, Investor Relations
amy.schwalm@organigram.ca
(416) 704-9057

For Media enquiries:
Ray Gracewood
Senior Vice President, Marketing and Communications
rgracewood@organigram.ca
(506) 645-1653

Friday, July 26th, 2019 Uncategorized Comments Off on $OGI Signs New Agreement for Access to 60,000kg of CBD-rich Hemp

$LXRP Agreement Increases Reach of Ingested Cannabis Absorption Technology

  • Cannabis users have historically preferred to inhale smoke from the burned plant in order to achieve rapid-onset absorption of its properties, but Lexaria Bioscience is making it possible to achieve similar results through oral ingestion
  • Lexaria’s revolutionary DehydraTECH technology allows cannabis users to eliminate the unhealthy effects of smoking from their routines, and the product is being tested with nicotine as well
  • Cannabis-infused edibles sales are expected to climb from about $1 billion currently to about $4.1 billion by 2022

Consumable bioactive product innovator Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) will expand the reach of its revolutionary DehydraTECH technology across the United States courtesy of a definitive five-year agreement that allows B2B hemp substance manufacturing firm Universal Hemp LLC to include it in many cannabidiol (CBD)-based food ingredients.

Lexaria’s DehydraTECH is an ingested drug delivery platform patented to work with all psychoactive and non-psychoactive cannabinoids…

Read more »

NOTE TO INVESTORS: The latest news and updates relating to LXRP are available in the company’s newsroom at http://nnw.fm/LXRP

 

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive instant SMS alerts, text STOCKS to 77948

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

Thursday, July 25th, 2019 Uncategorized Comments Off on $LXRP Agreement Increases Reach of Ingested Cannabis Absorption Technology

$YGYI 420 with CNW – Michigan Caregivers Grow More than a Million Marijuana Plants

The registered medical marijuana caregivers in Michigan are authorized to grow more than a million cannabis plants, according to state statistics. This information is crucial as the state transitions from a purely medical cannabis program to one that embraces the recreational use of the drug by adults.

Even if the state accelerates the process by which new commercial growers are licensed, it is unlikely that any of those licensees will have harvested, processed and distributed their marijuana crop at the time recreational sales are launched.

In August 2017, Andrew Brisbo, the Director of the Bureau of Medical Marijuana Regulation stated that approximately 43,000 patients had nominated a caregiver to grow a maximum of 12 cannabis plants for the medical use of the patient.

That statistic means that approximately 1.14 million marijuana plants are under the direct control of the registered caregivers in the state.

Currently, the number of caregivers on the medical marijuana program has risen to an estimated 47,000. This could mean that nearly 1.5 million cannabis plants are grown by these caregivers.

To put this figure in context, the 78 commercial cultivators with state-issued licenses have a 108,000 plant cultivation limit.

All the existing large scale growers and the caregivers currently supply the medical marijuana market whose current patient population stands at 300,000 (Michigan has the second strongest medical marijuana market in the country).

If recreational users come on board, the number of medical marijuana patients will be dwarfed by the number of adults who use cannabis recreationally. Statistics suggest that at least 1.54 million Michigan adults have used recreational marijuana at some point in their lives, so once recreational sales begin, the number of recreational users is likely to be five times that of medical marijuana users.

This means that Michigan could face the same supply shortages that have been witnessed in the states that transition from just medical marijuana markets to recreational cannabis as well. Such supply shortages normally trigger a frenzied expansion of cultivation capacity, which in turn causes a glut once all that extra marijuana finally enters the market.

To prevent the nosedive in prices which results from the glut, Michigan would be well advised to incorporate the caregiver-grown marijuana in the recreational market as well so that the recreational market is kept stable during its first months. This shouldn’t present any quality issues since the caregivers have been supplying the medical cannabis market of the state for years.

Analysts hope that the cannabis industry’s major players in Michigan and elsewhere, such as Youngevity International Inc. (NASDAQ: YGYI) and Willow Biosciences Corp. (CSE: WLLW), will welcome the caregivers whose role provides all-round benefits to all concerned.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have a questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

Thursday, July 25th, 2019 Uncategorized Comments Off on $YGYI 420 with CNW – Michigan Caregivers Grow More than a Million Marijuana Plants

$INMB Co-Founder and CEO Presents at 17th Annual #IDDST in Kyoto

LA JOLLA, Calif., July 25, 2019 — INmune Bio, Inc. (NASDAQ: INMB), an immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today announced that C.J. Barnum, Director of Neuroscience and R.J. Tesi, M.D., the company’s co-founder, and CEO, will present at the 17th Annual Congress of International Drug Discovery Science & Technology on July 26 in Japan.

Dr. Tesi’s talk is titled, “Combination Immunotherapy to Overcome Resistance to Cancer Treatments.” “Monotherapy with Checkpoint Inhibitors (CPI) is effective in only one of four patients. Combining CPI with other therapies may improve the outcome in patients unresponsive to monotherapy,” explained Dr. Tesi.

C.J. Barnum’s presentation is titled “Neurodegenerative Disease as an Immunological Disease: Role of Biomarkers.” “Neuroinflammation contributes to Alzheimer’s disease in some patients. Our Phase I trial uses a precision medicine approach to target this group of patients with dementia,” said Barnum.

The 17th Annual Congress of International Drug Discovery Science & Technology brings together leaders from across the immunotherapy industry and provides a unique opportunity for connecting scientists and facilitating the exchange of ideas and developments. Immunology-related drug targets are discussed to address the latest discoveries in the field.

About INmune Bio, Inc.
INmune Bio, Inc. is a publicly traded (NASDAQ: INMB) clinical-stage biotechnology company developing therapies targeting the innate immune system to fight disease. INmune Bio is developing three product platforms: two products that reengineer the patient’s innate immune system’s response to cancer and one product to treat neuroinflammation that is currently focused on Alzheimer’s disease. INKmune is a natural killer (NK) cell therapeutic that primes the patient’s NK cells to attack minimal residual disease, the remaining cancer cells that are difficult to detect, which often cause relapse. INB03 inhibits myeloid-derived suppressor cells (MDSC), which often cause resistance to immunotherapy, such as anti-PD-1 checkpoint inhibitors. XPro1595 targets neuroinflammation, which causes microglial activation and neuronal cell death. INmune Bio’s product platforms utilize a precision medicine approach for the treatment of a wide variety of hematologic malignancies, solid tumors and chronic inflammation. To learn more, please visit www.inmunebio.com.

INmune Bio Contact:
David Moss, CFO
(858) 964-3720
DMoss@INmuneBio.com

Media Contact:
Antenna Group
Sharon Golubchik
(201) 465-8008
INmuneBio@AntennaGroup.com

Thursday, July 25th, 2019 Uncategorized Comments Off on $INMB Co-Founder and CEO Presents at 17th Annual #IDDST in Kyoto

$PBIO First Sale of BaroShear K45, Revolutionary Water-Soluble CBD Manufacturing System

Pressure BioSciences (OTCQB: PBIO), a leader in the development and sale of broadly enabling, pressure-based technology and products to the worldwide life sciences and other industries, today announced the initial sale of its revolutionary BaroShear(TM) K45 processing system. According to the update, the novel instrument system is based on the company’s proprietary Ultra Shear Technology(TM) (“UST”) platform and is designed to resolve one of the most critical problems facing CBD manufacturers today: the extremely poor water solubility of CBD Oil. “We are thrilled to be the first purchaser of the BaroShear K45 system,” Nano CBD Cosmetics LLC Founder Christopher Holden stated in the news release. “This groundbreaking technology will enable companies producing nano-scale CBD emulsion products to meet the ever-increasing demand for CBD nanoemulsion products. In fact, our own nano-CBD products are currently selling faster than we can produce them. However, with PBI’s cutting-edge technology, we expect to increase our nano-emulsified, water-soluble CBD production capacity to many multiples of what it is today…and that is huge.”

To view the full press release, visit: http://nnw.fm/AE1bj

About Pressure BioSciences Inc.

Pressure BioSciences (OTCQB: PBIO) is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences industry. The company’s products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or “PCT”) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control biomolecular interactions (e.g., cell lysis, biomolecule extraction). PBIO’s primary focus is in the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil and plant biology, forensics and counter-bioterror applications. Additionally, major new market opportunities have emerged in the use of its pressure-based technologies in the following areas: (1) the use of its recently acquired PreEMT technology from BaroFold Inc. to allow entry into the biologics contract research services sector, and (2) the use of its recently patented, scalable, high-efficiency, pressure-based Ultra Shear Technology (“UST”) platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and (ii) prepare higher quality, homogenized, extended shelf-life or room temperature stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies. For more information, visit the company’s website at www.PressureBiosciences.com.

NOTE TO INVESTORS: The latest news and updates relating to PBIO are available in the company’s newsroom at http://nnw.fm/PBIO

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive instant SMS alerts, text STOCKS to 77948

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

Thursday, July 25th, 2019 Uncategorized Comments Off on $PBIO First Sale of BaroShear K45, Revolutionary Water-Soluble CBD Manufacturing System

$TCAN Thousands Submit Comments Urging FDA to Allow CBD in Supplements and Foods

The U.S. Food and Drug Administration (FDA) started receiving comments on CBD regulation from the public and other stakeholders in April and the comments period came to an end early last week.

The agency had initially planned to close the comments period on July 2 but the overwhelming public interest in the matter led the FDA to extent that deadline to July 16. By the close of the comments period, more than 4,400 submissions had been filed by individuals and organization.

The comments received covered everything imaginable about the therapeutic effects of CBD, how the compound should be tested, packaged and marketed, as well as matters of consumer protection and law enforcement.

There were hundreds of comments from individuals who claimed that CBD had helped them to deal with the symptoms of different health challenges, such as pain and anxiety. Other people claimed that they were able to wean themselves off of other drugs that had serious side effects by using CBD.

Several health associations and medical professionals submitted comments to the effect that the agency should regulate CBD as a health supplement as long as strict labeling and quality standards are set for manufacturers.

The Dravet Syndrome Foundation submitted a comment urging the FDA to formulate regulations that standardize the labeling of CBD supplements on matters of concentration, stability and the ingredients in the products since Dravet syndrome sufferers have been turning to these products after failing to get relief from the existing remedies.

A group of 37 state attorneys general also wrote to the FDA asking the agency to formulate rules that would protect consumers by requiring manufacturers to provide accurate information about the risks and potential benefits of CBD products. This would enable consumers to make an informed decision about the CBD products they use.

The Center for Science in the Public Interest (CSPI) submitted their comment requesting the FDA to design a program through which the state laws on CBD and other related products could be gradually aligned with the federal regulations on these products. By bringing uniformity to the CBD rules across different jurisdictions, the FDA will have taken a significant step towards safeguarding consumers from adulterated, mislabeled and contaminated CBD products, CSPI added.

The National Association of State Departments of Agriculture (NASDA) called on the FDA to work closely with them in order to find ways to regulate the industry without stifling its growth.

The FDA will use these comments, along with any other input it receives from other fora, such as a planned hemp conference next month, while formulating the draft rules for the hemp industry which are slated to be released in August.

Marijuana industry analysts believe that players like VIVO Cannabis Inc. (TSX.V: VIVO) (OTCQX: VVCIF) and TransCanna Holdings Inc. (CSE: TCAN) (FRA: TH8), will be eager to see what rules are finally released since CBD products could be an additional moneymaker for these entities.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have a questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

Wednesday, July 24th, 2019 Uncategorized Comments Off on $TCAN Thousands Submit Comments Urging FDA to Allow CBD in Supplements and Foods

$TGODF Strong Demand for CBD Edibles to Create a $4.1 Billion Market by 2022

Palm Beach, FL – July 24, 2019 – The CBD story has been on the of the most explosive to date for investors.  In fact, multi-billion-dollar industries are just now being transformed by CBD, including alcohol, health and wellness, cigarettes, and the retail industry.  It’s impacting a range of food, too. Everything from gummy bears and cookies to candy and brownies are being infused with CBD with considerable consumer demand.  Interesting to note, consumer spending on cannabis-based food and drink reached $1 billion in 2017 just in the U.S. in Canada. By 2022, that could be up to $4.1 billion, according to analysts at Arcview Market Research.  That’s opening a wide range of opportunity for companies including Naturally Splendid Enterprises Ltd. (OTCQB:NSPDF) (TSX-V:NSP), Charlotte’s Web Holdings Inc. (OTCQX:CWBHF) (CSE:CWEB), The Green Organic Dutchman Holdings Ltd. (OTCQX:TGODF) (TSX:TGOD), Curaleaf Holdings Inc. (OTCQX:CURLF) (CSE:CURA), and Green Thumb Industries Inc. (OTCQX:GTBIF) (CSE:GTII).

Naturally Splendid Enterprises Ltd. (OTCQB:NSPDF) (TSX-V:NSP) BREAKING NEWS: Naturally Splendid Enterprises Ltd. just announced unaudited gross sales in the second quarter of 2019 nearly doubled compared to the same period last year.  Naturally Splendid has recorded approximately $1,000,000 CDN in gross sales during the second quarter (Q2) of 2019, which spans the period from April 1, 2019 to June 30, 2019. The Company previously reported gross sales of $483,675 CDN in the second quarter (Q2) of 2018, which spanned the period from April 1, 2018 to June30, 2018. Accumulative gross sales for Q1 and Q2 of 2019 are approximately $1,715,000 CDN almost equaling the gross sales for the entire year in 2018.  In comparison, the Company recorded audited gross annual sales of $2,073,776 CDN in 2018 and audited gross sales of $1,550,469 CDN in 2017. Currently the Company is on pace to surpass 2018 total gross sales early in the third quarter of this year.

Naturally Splendid is experiencing growth in gross sales in many of its divisions. The core concept of duo revenue streams emanating from producing and distributing Company branded products, as well as offering Contract Manufacturing Services has provided a foundation to leverage these assets and drive sustainable shareholder value.  Sales of the Company’s recently launched Natera Sport KEY-TO-LIFE keto bars continue increase as distribution points for this product expand throughout Canada including Whole Foods, Sobeys’s, Loblaws, Longo’s, Metro, Save-On- Foods, Nature’s Fare and No Frills, as well as many more retailers across the country in just the first three (3) months of the official launch date.

“The significant time and strategically deployed capital allotted to the continued advancement of Naturally Splendid’s manufacturing facilities has positioned the Company as both a premier manufacturer of healthy food products, but has also establish Naturally Splendid as an early mover in the evolving cannabis edibles market,” says Naturally Splendid President Craig Goodwin.  “We are definitely pleased with the increase in our gross sales throughout our divisions. More importantly, we believe the Company is reaching the stage of being cash flow positive on a more consistent basis. This is due in fact to not only the increased gross sales, but also increasing margins as scales of economy begin to show a positive effect on our bottom line. As the Company approaches being cash flow positive, we can begin to focus more attention and resources towards the lucrative omega markets globally and focus attention on the positively evolving cannabinoid opportunities, specifically focusing on the Cannabidiol (CBD) markets.”  For more information on NSP, please visit:  https://www.naturallysplendid.com/

Other cannabis-related developments from around the markets include:

 

Charlotte’s Web Holdings Inc. (OTCQX:CWBHF) (CSE:CWEB) just unveiled its newest CBD product line – hemp extract-infused CBD Gummies – made with whole-plant extract from its prized hemp genetics and featuring synergistic functional ingredients to support specific health related functions including everyday stress, sleep, and recovery from exercise or active lifestyles.  Available in a variety of flavors, gummies are the latest addition to the Company’s expanding line of CBD hemp-extract products. “Gummies are a very popular edible format as a result of convenience and measurable consumption,” stated Kelsey Morrison, Associate Director of Product Development at Charlotte’s Web. “This new delivery format from Charlotte’s Web provides an easy bite-sized way to ingest full-spectrum hemp-extract CBD.”

The Green Organic Dutchman Holdings Ltd. (OTCQX:TGODF) (TSX:TGOD)just announced its  expansion into the global organic hemp CBD market with the launch of its Global Strategic Hemp Division. This new division will leverage TGOD’s solid expertise in the European hemp CBD market to fuel growth and accelerate the development and commercialization of new products across its network of international partners. “With the global CBD market expected to hit $22 billion in less than 3 years, it is clear that the segment is drawing substantial consumer demand,” commented Brian Athaide, CEO of TGOD. “Our team has years of direct hands-on experience in the CBD space and we are excited to use this advantage to execute on a fast-moving market expansion strategy. CBD is a wellness product and has a natural fit with TGOD’s certified organic positioning and the large segment of consumers who are increasingly demanding natural and organic products. The time to act is now, and TGOD has the team, the infrastructure and the capital to establish a significant presence in this market.”

Curaleaf Holdings Inc. (OTCQX:CURLF) (CSE:CURA) just issued the following statement in response to a letter from the U.S. Food and Drug Administration regarding its CBD product marketing. Curaleaf is committed to the highest standards of quality and compliance, and will work collaboratively with the FDA to resolve all issues addressed in the agency’s letter. The Company will respond to the FDA letter within the required 15 working days. Compliance is a top priority for Curaleaf and the Company is fully committed to complying with FDA requirements for all of the products that it markets. We can affirm that nothing in the letter raises any issues concerning the quality and consistency of any Curaleaf product or calls into question the high safety standards of the Company’s cultivation and manufacturing processes. Curaleaf CBD products are all derived from hemp and meet the requirements of the Farm Bill.

Green Thumb Industries Inc. (OTCQX:GTBIF) (CN:GTII), a leading national cannabis consumer packaged goods company and owner of Rise and Essence retail stores, announced it will open its fourth retail location in Florida, Rise Oviedo, the community’s first cannabis store, on July 9, 2019. This is GTI’s 26th open location in the country.  Rise Deerfield Beach, Rise Pinellas Park and Rise Bonita Springs all opened earlier this year, and GTI has a retail footprint for up to 35 stores throughout Florida. The company owns and operates a manufacturing facility in Homestead where it cultivates and produces GTI’s branded cannabis products including Rhythm and The Feel Collection. “We are honored to be the first company to provide access to medical cannabis in Oviedo and to help Floridians exercise their right to wellness,” said GTI Founder and Chief Executive Officer Ben Kovler. “Our Rise stores provide exceptional customer care and we’re thrilled to serve the people of Oviedo and surrounding communities.”

DISCLAIMER:  FN Media Group LLC (FNM), which owns and operates Financialnewsmedia.com and MarketNewsUpdates.com, is a third- party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels.  FNM is NOT affiliated in any manner with any company mentioned herein.  FNM and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security.  FNM’s market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities.  The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material.  All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks.  All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release.  FNM is not liable for any investment decisions by its readers or subscribers.  Investors are cautioned that they may lose all or a portion of their investment when investing in stocks.  For current services performed FNM expects to be compensated twenty-five hundred dollars for news coverage of the current press release issued by Naturally Splendid Enterprises Ltd. by a non-affiliated third party.  FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNM undertakes no obligation to update such statements.

Wednesday, July 24th, 2019 Uncategorized Comments Off on $TGODF Strong Demand for CBD Edibles to Create a $4.1 Billion Market by 2022

$PBIO Announces Second Major Contract for BaroFold Protein Refolding, Disaggregation Services

Company Expects Significant Services Revenue Increase in 2019 as it Expands its BaroFold Platform into the Estimated $44 Billion Global Bioprocess Technology Market

SOUTH EASTON, MA / July 24, 2019 / Pressure BioSciences, Inc. (OTCQB: PBIO) (“PBI” and the “Company”), a leader in the development and sale of broadly enabling, high pressure-based instruments, platform technologies and related consumables for the worldwide life sciences industry, today announced it has signed a contract services agreement with a world-renown, multi-billion dollar biotherapeutics company to enhance the process manufacturing of one of their candidate protein drugs.

The manufacturing of therapeutic proteins can be a complex and challenging process. According to a report in F1000 Research (Lagasse, Feb 2017), producing a typical protein drug may include more than 5,000 critical steps. Two of the major challenges associated with manufacturing recombinant proteins are (i) the formation of aggregates, and (ii) protein misfolding. These are significant issues that can prevent a protein drug candidate from ever making it to market. PBI’s BaroFold™ technology platform offers a unique and cost-effective way to address these manufacturing challenges.

PBI purchased the assets of BaroFold, Inc. in late 2017, including their extensive patent portfolio. Since that time, the Company has incorporated its own proprietary technology and developed a cost-effective way to improve the process manufacturing of proteins by utilizing high pressure. To capitalize on these capabilities, PBI launched the BaroFold Biopharma Services Business in January 2019.

Dr. Alexander Lazarev, Chief Science Officer of PBI, said: “The BaroFold platform can be applied to the development and production of many different therapeutic proteins, can improve product safety, and is scalable and practical for standard bioprocess environments. Moreover, it offers ways to reduce or eliminate the use of aggressive chemicals in the protein manufacturing process. Thus, we believe this unique technology platform can help biopharmaceutical companies create and manufacture high quality novel protein therapeutics and biosimilars, lower the cost of existing formulations, and help protect our environment.”

Protein-based therapeutics are a large and growing part of the global healthcare industry. Based on data in the THPdb database (http://crdd.osdd.net/raghava/thpdb/), there are over 200 therapeutic proteins and peptides currently approved by the FDA for clinical use in the US. These target therapies have shown significantly improved outcomes for many patients suffering from severe medical conditions, such as cancer and immunological diseases. According to a report from Research and Markets (May 2016), the global protein drug market will reach approximately $248 billion by 2020.

Richard T. Schumacher, President and CEO of PBI, commented: “Our proprietary BaroFold Biopharma Services Business offers us a unique opportunity to enter the estimated $44 billion (by 2026) global bioprocess technology market (Transparency Market Research, July 2018). In addition to successfully performing contract services for two biopharmaceutical companies since the beginning of 2019, we are also in discussions with three additional biopharmaceutical companies interested in utilizing our proprietary BaroFold services for their protein drug candidates. To take full advantage of this opportunity, we have doubled the capacity of our contract services team, purchased additional sophisticated equipment, and developed new high-pressure concepts that further improve and enhance our BaroFold process scalability and its GMP compliance.”

Mr. Schumacher concluded: “We believe our recently launched BaroFold Biopharma Services Business could add as much as $500,000 to 2019 total revenue and significantly more to total revenue for 2020 and beyond. It is important to note that these estimates do not include the anticipated growth in Barocycler™ 2320EXT sales that we believe will result from biotechnology and biopharmaceutical companies developing their own manufacturing, quality control, and protein characterization applications on our leading PCT-based instrument system. These are truly exciting times for all stakeholders in PBI.”

About the BaroFold Technology Platform

The BaroFold™ platform is a patented technology that employs carefully controlled high pressure for the disaggregation and controlled refolding of recombinant proteins into their native structures for desired drug activity. The BaroFold technology platform is transformative and practical for biopharmaceutical manufacturing processes, offering substantially reduced production costs due to its increased process yield and throughput in both mammalian and non-mammalian systems. The BaroFold technology platform is easily scalable and has been utilized for the cGMP production of pre-clinical and phase 1 through phase 3 clinical materials.

About Pressure BioSciences, Inc.

Pressure BioSciences, Inc. (OTCQB: PBIO) is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences industry. Our products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or PCT) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions (e.g., cell lysis, biomolecule extraction). Our primary focus is in the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil & plant biology, forensics, and counter-bioterror applications. Additionally, major new market opportunities have emerged in the use of our pressure-based technologies in the following areas: (1) the use of our recently acquired, patented technology from BaroFold, Inc. (the “BaroFold” technology) to allow entry into the bio-pharma contract services sector, and (2) the use of our recently-patented, scalable, high-efficiency, pressure-based Ultra Shear Technology (“UST”) platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., CBD Oil and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room temperature stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies.

Forward Looking Statements

This press release contains forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry’s actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied or inferred by these forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “could,” “would,” “expects,” “plans,” “intends,” “anticipates,” “believes,” “estimates,” “predicts,” “projects,” “potential” or “continue” or the negative of such terms and other comparable terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. In evaluating these statements, you should specifically consider various factors. Actual events or results may differ materially. These and other factors may cause our actual results to differ materially from any forward-looking statement. These risks, uncertainties, and other factors include, but are not limited to, the risks and uncertainties discussed under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law.

For more information about PBI and this press release, please click on the following website link:
http://www.pressurebiosciences.com
Please visit us on Facebook, LinkedIn, and Twitter.

Investor Contacts:
Richard T. Schumacher, President and CEO
(508) 230-1828 (T)

Alexander Lazarev, Ph.D., Chief Science Officer
(508) 230-1829 (F)

Wednesday, July 24th, 2019 Uncategorized Comments Off on $PBIO Announces Second Major Contract for BaroFold Protein Refolding, Disaggregation Services